Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
CAMBRIDGE, Mass., April 17, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, will report first quarter 2017 financial results after the Nasdaq Global Market closes on Thursday, April 27, 2017. Subsequently, at 4:30 p.m., Eastern Time, Edward Kaye, M.D., Sarepta’s chief executive officer, Sandy Mahatme, Sarepta’s chief financial officer and chief business officer, and Bo Cumbo, Sarepta’s head of global commercial will host a conference call to discuss first quarter 2017 financial results and to provide a corporate update.
The conference call may be accessed by dialing 574-990-1451 for domestic callers and 1-844-534-7313 for international callers. The passcode for the call is 9321329. Please specify to the operator that you would like to join the "Sarepta First Quarter 2017 Earnings Call." The conference call, along with a slide presentation, will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit us at www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
